What is F-star Therapeutics Earnings Power Value (EPV)?
As of Sep22, F-star Therapeutics's earnings power value is $1.05. *
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.
Margin of Safety is
N/A.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.
F-star Therapeutics Earnings Power Value (EPV) Historical Data
The historical data trend for F-star Therapeutics's Earnings Power Value (EPV) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
F-star Therapeutics Earnings Power Value (EPV) Chart
|
F-star Therapeutics Annual Data
|
|
Trend |
Dec19 |
Dec20 |
Dec21 |
| Earnings Power Value (EPV) |
|
- |
- |
- |
|
F-star Therapeutics Quarterly Data
|
|
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
| Earnings Power Value (EPV) |
Get a 7-Day Free Trial
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of F-star Therapeutics's Earnings Power Value (EPV)
For the Biotechnology subindustry, F-star Therapeutics's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
F-star Therapeutics's Earnings Power Value (EPV) Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, F-star Therapeutics's Earnings Power Value (EPV) distribution charts can be found below:
* The bar in red indicates where F-star Therapeutics's Earnings Power Value (EPV) falls into.
F-star Therapeutics Earnings Power Value (EPV) Calculation
Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.
F-star Therapeutics (F-star Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
Babraham Research Campus, Eddeva B920, Cambridge, GBR, CB22 3AT
F-star Therapeutics Inc is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the company's goal is to offer patients greater and more durable benefits than immuno-oncology treatments.
Executives
| Geoffrey Race |
director |
C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT |
| Edward Jr Benz |
director |
C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT |
| Darlene M Deptula-hicks |
officer: See Remarks |
C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062 |
| Eliot Forster |
director, officer: PRESIDENT AND CEO |
C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT |
| Nessan Bermingham |
director |
890 WINTER STREET, WALTHAM MA 02451 |
| Louis Kayitalire |
officer: CHIEF MEDICAL OFFICER |
C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT |
| Neil Brewis |
officer: CHIEF SCIENTIFIC OFFICER |
C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT |
| Pamela M. Klein |
director |
35 PARKWOOD DRIVE, SUITE 210, HOPKINTON MA 01748 |
| Krol Patrick Johan Hendrik |
director |
GUSTAV MAHLERPLEIN 3, AMSTERDAM P7 1082 MS |
| Garrett Winslow |
officer: General Counsel and Secretary |
35 PARKWOOD DRIVE, C/O SPRING BANK PHARMACEUTICALS, INC., HOPKINTON MA 01748 |
| Lori Firmani |
officer: VP of Finance and Treasurer |
35 PARKWOOD DRIVE, C/O SPRING BANK PHARMACEUTCALS, INC., HOPKINTON MA 01748 |
| Scott Andrew Smith |
director |
C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901 |
| Timothy P Clackson |
director |
C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
| Christiana Bardon |
director, 10 percent owner |
86 SOUTH STREET, C/O SPRING BANK PHARMACEUTICALS, INC., HOPKINTON MA 01748 |
| Mpm Oncology Impact Management Lp |
10 percent owner |
399 BOYLSTON STREET, SUITE 1100, BOSTON MA 02116 |
F-star Therapeutics (F-star Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FSTX has been successfully added to your